X

Company profile for PEDIATRIC PHARMACEUTICALS INC

PEDIATRIC PHARMACEUTICALS INC

PEDIATRIC PHARMACEUTICALS INC

About, Contact Details

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

No Presentations

VIDEO(s)

No Video

DIGITAL CONTENT

No Content

APIs // Active Pharmaceutical Ingredients

1 APIs, 1 USDMF

DEVELOPMENTS

No Content

Contact Supplier

Related Companies

Pediatric Pharmaceuticals, Inc. (PPI) was formed to develop and market unique pharmaceutical products designed to fulfill the needs of the medical community. Its first product CAFCIT, caffeine citrate for apnea of prematurity, received FDA approval in September 1999 and is now on the market throughout the U.S. PPI plans to target the development of pharmaceuticals, many of which will qualify as orphan drugs capa...

Pediatric Pharmaceuticals, Inc. (PPI) was formed to develop and market unique pharmaceutical products designed to fulfill the needs of the medical community. Its first product CAFCIT, caffeine citrate for apnea of prematurity, received FDA approval in September 1999 and is now on the market throughout the U.S. PPI plans to target the development of pharmaceuticals, many of which will qualify as orphan drugs capable of obtaining the financial/patent benefits of the Orphan Drug Act. Major drug companies are usually not interested in these products because of their relatively small sales potential. The Company also feels that once certain specialty products are approved, they may find a larger audience through use in other indications. As long term strategy, PPI plans to identify and financially support selected university and hospital research projects that offer strong potential as major pediatric and adult products. This investment program should provide the Company with a stream of new and innovative products as well as foster formal relationships with leading medical research centers. PPI first became interested in thalidomide after supplying the product for children and adults afflicted with leprosy at the Hansen's Disease Center in Carville, LA. An analysis of existing literature indicated the potential for the product in a number of different areas. For the past ten years we have been supplying investigators who have obtained an IND from the FDA.